BACKGROUND: Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). METHODS:Healthy adults 18-49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135 μg or 45 μg, or rHA 45 μg, 15 μg, 7.5 μg or 3.8 μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42. RESULTS:392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135 μg and 45 μg groups, and 82%, 75%, 66%, and 72% in those receiving 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE groups, respectively. CONCLUSIONS:rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control.
RCT Entities:
BACKGROUND: Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). METHODS: Healthy adults 18-49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135 μg or 45 μg, or rHA 45 μg, 15 μg, 7.5 μg or 3.8 μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42. RESULTS: 392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135 μg and 45 μg groups, and 82%, 75%, 66%, and 72% in those receiving 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE groups, respectively. CONCLUSIONS: rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control.
Authors: Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards Journal: Immunol Rev Date: 2018-07 Impact factor: 12.988
Authors: Lucia Fischetti; Ziyun Zhong; Christopher L Pinder; John S Tregoning; Robin J Shattock Journal: Cytokine Date: 2017-08-18 Impact factor: 3.861
Authors: Anthony L Desbien; Natasha Dubois Cauwelaert; Steven J Reed; Hilton R Bailor; Hong Liang; Darrick Carter; Malcolm S Duthie; Christopher B Fox; Steven G Reed; Mark T Orr Journal: J Immunol Date: 2016-10-28 Impact factor: 5.422
Authors: Kailash P Patra; Fengwu Li; Darrick Carter; James A Gregory; Sheyenne Baga; Steven G Reed; Stephen P Mayfield; Joseph M Vinetz Journal: Infect Immun Date: 2015-02-17 Impact factor: 3.441
Authors: Reed F Johnson; Drishya Kurup; Katie R Hagen; Christine Fisher; Rohan Keshwara; Amy Papaneri; Donna L Perry; Kurt Cooper; Peter B Jahrling; Jonathan T Wang; Jan Ter Meulen; Christoph Wirblich; Matthias J Schnell Journal: J Infect Dis Date: 2016-07-24 Impact factor: 5.226
Authors: Emilie Seydoux; Hong Liang; Natasha Dubois Cauwelaert; Michelle Archer; Nicholas D Rintala; Ryan Kramer; Darrick Carter; Christopher B Fox; Mark T Orr Journal: J Immunol Date: 2018-05-16 Impact factor: 5.422